OERLIKON
Oerlikon presents a full range of innovative customized safety components for Battery Electric Vehicles (BEVs), including pioneering heat shields, gas guidance systems, and cell separators. In the event of a battery fire, they improve the heat protection and electrical and mechanical strength of the batteries, which can save passengers' lives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606775871/en/
Heat resistant parts such as Oerlikon’s high performance customizable heat shields with superior thermal and electrical insulation increase the safety of battery systems. (Image source: OERLIKON)
Thermal runaway poses a significant challenge in high-performance battery systems and can potentially cause extensive vehicle damage or endanger passengers. “Oerlikon is renowned in the automotive market for its engineering expertise and materials innovation. Now we combine carefully engineered cutting-edge heat-resistant materials with an intelligent design to create thermal insulation systems that are redefining industry standards,” said Marcus Spreckels, Head of Technology TIS.
Highly heat-resistance yet thin and lightweight
The portfolio covers all critical components, from heat shields and gas guidance components to cell separators, to address the needs of any battery system and risk level. They are highly heat-resistant, mechanically durable, and yet ultra-light and thin. They insulate the critical high-voltage infrastructure of the batteries electrically and thermally, thus reducing the likelihood of battery fires spreading to the passenger area at an early stage.
From meeting the basic regulatory standards of the UN Electric Vehicle Safety Regulation (GTR 20) and their often more stringent adoption in individual countries, to exceeding the advanced requirements with Stop/Zero TP and limp-home functionality, the components are both versatile and reliable.
No compromise: customized solutions for any requirement
Unlike other manufacturers, Oerlikon does not offer standard products. Marcus Spreckels: "We develop customized solutions in terms of material and design, taking into account the specific safety requirements of each battery concept without compromising on space or weight."
This is where Oerlikon's experience in automotive engineering comes into play: all components are 3D-moldable, so they can be optimally tailored to the design of the battery system and the vehicle, for maximum protection. Each solution is fully customized and ready to install according to individual requirements.
Combining materials science know-how and automotive experience
Oerlikon's thermal insulation solutions across all safety concepts and battery types on the market represent a new standard in the industry. With their deep knowledge in material science, Oerlikon's engineers have created heat-resistant materials with new properties. Furthermore, Oerlikon's decade-long experience in the automotive market allows customers to benefit from customized solutions from a certified manufacturer who is well-versed in the challenges associated with designing vehicles.
Series production for the entire portfolio has started at the Bremen site in the first quarter of 2024.
IATF 16949 certified and using only mica-free materials in its solutions, Oerlikon is committed not only to advancing vehicle safety, but also to environmental responsibility and ethical materials sourcing.
Visit Oerlikon at the Battery Show Europe in Stuttgart, Hall 8, Booth G85! Come by to explore our pioneering multifunctional thermal insulation solutions and meet the developers.
For interviews or more information, please contact us.
About the Oerlikon Surface Solutions Division
Oerlikon is a leading global provider of surface and additive manufacturing solutions and services. The division offers an extensive portfolio of market-leading thin-film, thermal spray and additive manufacturing technologies, equipment, components and materials. Emission reduction in transportation, maximized longevity and performance of tools and components, increased efficiency and intelligent materials are hallmarks of its leadership. Pioneering technology for decades, the division serves customers with standardized and customized solutions across a worldwide network of more than 170 sites in 37 countries.
With its technology brands – Oerlikon Balzers, Oerlikon Metco and Oerlikon AM – the Oerlikon Surface Solutions division focuses on technologies and services that improve and maximize performance, function, design, reliability and sustainability, which are innovative, game-changing advantages for customers in the automotive, aviation, tooling and general industries and in the luxury, medical, semiconductors, power generation and oil & gas markets.
The division is part of the publicly listed Oerlikon Group (SIX: OERL), headquartered in Switzerland, which has 12,600 employees and generated CHF 2.7 billion in revenue in 2023.
For more information see: www.oerlikon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606775871/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom